Bristol-Myers Squibb (NYSE:BMY) – Stock analysts at Truist Securiti issued their Q1 2021 earnings per share estimates for Bristol-Myers Squibb in a research note issued to investors on Thursday, February 4th. Truist Securiti analyst G. Gilbert expects that the biopharmaceutical company will post earnings per share of $1.76 for the quarter. Truist Securiti also issued estimates for Bristol-Myers Squibb’s Q2 2021 earnings at $1.91 EPS, Q4 2021 earnings at $1.77 EPS, FY2021 earnings at $7.41 EPS, FY2022 earnings at $7.89 EPS, FY2023 earnings at $8.08 EPS, FY2024 earnings at $8.13 EPS and FY2025 earnings at $7.57 EPS.
A number of other brokerages have also issued reports on BMY. Guggenheim upgraded Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $70.00 target price on the stock in a research report on Monday, October 19th. Smith Barney Citigroup increased their target price on Bristol-Myers Squibb from $73.00 to $77.00 in a research report on Monday, November 30th. Sanford C. Bernstein reiterated a “market perform” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, November 10th. Societe Generale upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $76.00 price objective on the stock in a report on Monday, November 16th. Finally, Truist initiated coverage on Bristol-Myers Squibb in a report on Friday, October 23rd. They issued a “hold” rating and a $65.00 price objective on the stock. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $73.75.
Shares of NYSE:BMY opened at $59.76 on Monday. Bristol-Myers Squibb has a 1 year low of $45.76 and a 1 year high of $67.55. The firm has a market capitalization of $135.22 billion, a price-to-earnings ratio of -543.22, a price-to-earnings-growth ratio of 1.00 and a beta of 0.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.67 and a quick ratio of 1.58. The business’s 50 day moving average price is $62.94 and its 200-day moving average price is $72.12.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Wednesday, February 3rd. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.42 by $0.04. Bristol-Myers Squibb had a positive return on equity of 27.48% and a negative net margin of 0.11%. The business had revenue of $11.07 billion for the quarter, compared to analyst estimates of $10.74 billion. During the same quarter in the prior year, the firm posted $1.22 EPS. The business’s quarterly revenue was up 39.3% compared to the same quarter last year.
Several large investors have recently modified their holdings of BMY. Fiduciary Planning LLC acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth about $25,000. Founders Capital Management acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $31,000. Penbrook Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $34,000. Black Swift Group LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $49,000. Finally, HBC Financial Services PLLC increased its position in shares of Bristol-Myers Squibb by 30.3% during the 4th quarter. HBC Financial Services PLLC now owns 800 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 186 shares during the last quarter. 72.41% of the stock is owned by hedge funds and other institutional investors.
In other Bristol-Myers Squibb news, SVP Adam Dubow sold 900 shares of the firm’s stock in a transaction on Tuesday, November 24th. The stock was sold at an average price of $63.39, for a total value of $57,051.00. Following the completion of the sale, the senior vice president now directly owns 15,186 shares of the company’s stock, valued at approximately $962,640.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rupert Vessey sold 57,591 shares of the firm’s stock in a transaction dated Thursday, November 19th. The stock was sold at an average price of $61.30, for a total value of $3,530,328.30. Following the sale, the executive vice president now directly owns 46,142 shares of the company’s stock, valued at $2,828,504.60. The disclosure for this sale can be found here. Insiders sold a total of 71,915 shares of company stock valued at $4,410,814 over the last ninety days. Corporate insiders own 0.14% of the company’s stock.
The business also recently announced a quarterly dividend, which was paid on Monday, February 1st. Shareholders of record on Monday, January 4th were paid a $0.49 dividend. The ex-dividend date of this dividend was Thursday, December 31st. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.45. This represents a $1.96 dividend on an annualized basis and a dividend yield of 3.28%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.79%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
Further Reading: Trading Penny Stocks
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.